Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 1998, for National Research Corporation (NRC Health). The company provides market research services, primarily renewable performance tracking, syndicated services, and custom research. As of May 1, 1998, there were 7,305,000 shares of common stock outstanding. The company transitioned from S Corporation to C Corporation status on October 14, 1997, following its initial public offering.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Total Revenues | $3,406,100 | $3,439,794 |
| Operating Income | $656,558 | $1,053,974 |
| Net Income | $561,758 | $1,099,041 |
| Pro Forma Net Income | $561,758 | $659,427 |
| Net Cash from Operating Activities | $1,922,980 | $597,363 |
| Cash and Cash Equivalents (End of Period) | $3,893,360 | $4,311,357 |
| Working Capital | $18,067,714 | N/A |
| Operating Margin | 19.3% | 30.7% |
Material Changes vs. Prior Period
- Revenue Stability: Total revenues remained relatively flat at approximately $3.4 million. However, the mix shifted: Renewable performance tracking services declined 2.9% due to the loss of a major client (Kaiser Permanente-Northern California), while custom research revenue increased 39.2% due to project timing.
- Expense Growth: Total operating expenses increased 15.3% to $2.75 million. Direct expenses rose 8.3% as the company maintained its labor force despite revenue reductions from the lost client. Selling, general, and administrative (SG&A) expenses surged 25.0% due to sales force expansion and costs associated with being a public company.
- Profitability Decline: Operating income dropped 37.7% to $656,558, and net income fell 48.9% to $561,758. The decline in net income is partially attributed to the new provision for income taxes ($357,000) resulting from the company's C Corporation status, whereas the prior year had no tax provision as an S Corporation.
- Cash Flow Improvement: Net cash provided by operating activities increased significantly to $1.92 million from $597,000, driven by the collection of a $717,000 receivable and timing differences in billings.
Guidance, Outlook, and Risks
- Liquidity: The company maintains strong liquidity with $3.9 million in cash and $18.1 million in working capital. Cash flow from operations remains sufficient for working capital and capital expenditures.
- Investing Activities: Net cash used in investing activities was $2.7 million, primarily due to the purchase of marketable debt securities ($4.4 million) and capital expenditures ($287,000) for equipment and software.
- Deferred Revenue: The company holds $2.16 million in billings in excess of revenues earned (deferred revenue), which is expected to be recognized within 12 months.
- Accounting Changes: The company adopted SOP 98-1 regarding internal use software, capitalizing approximately $195,000 of development costs in Q1 1998, whereas these were previously expensed.
- Risks: The loss of the Kaiser Permanente client highlights concentration risk in the performance tracking segment. Additionally, the transition to a public company has increased fixed SG&A costs.
Key Facts for Investor Verification
- Verify the replacement strategy for the lost Kaiser Permanente-Northern California client and its impact on future revenue stability.
- Monitor the trajectory of SG&A expenses to ensure they do not continue to outpace revenue growth as the company scales its sales force.
- Confirm the sustainability of the improved operating cash flow, which was heavily influenced by the timing of a specific $717,000 receivable collection.
- Review the utilization of the $16.8 million in net proceeds from the October 1997 IPO, currently held in short-term government securities.
- Assess the impact of the new income tax provision on future net income margins compared to the pro forma figures.